FDA Grants Bayer Accelerated Approval for Lung Cancer Therapy HYRNUO

Key Facts

1The U.S. FDA granted accelerated approval to Bayer's HYRNUO (sevabertinib) as a first-line therapy for HER2-mutated non-small cell lung cancer.

In a move reflecting the ongoing advancement in targeted oncology treatments, Bayer has announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for its drug HYRNUO (sevabertinib). According to reports, the therapy is approved as a first-line treatment for patients with HER2-mutated non-small cell lung cancer (NSCLC). This regulatory milestone provides a new targeted option for this specific mutation based on clinical data supporting its efficacy.

This approval strengthens Bayer's position within the specialized pharmaceutical sector, potentially driving long-term revenue growth as a primary treatment option. Per market data, the FDA's decision underscores the significance of Bayer's oncology pipeline and its ability to deliver innovative biotechnology solutions in a highly competitive global healthcare landscape.

Bayer's stock (BAYRY) stood at $14.31 at close on September 09, 2026, having traded between a day high of $14.46 and a low of $14.25. Investors will be monitoring further updates regarding the commercial rollout of the therapy, while broader market sentiment remains influenced by recent economic data, including the U.S. Non-Farm Payrolls report which showed 162k jobs added earlier this month.